Alpine Immune Sciences, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2015-01-23

Employees: 142

Market Cap: $4.4B

Website: http://www.alpineimmunesciences.com

Clinical Trials

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias

Phase 1

Recruiting

Conditions: Immune Thrombocytopenia
Idiopathic Thrombocytopenic Purpura
Cold Agglutinin Disease
Warm Autoimmune Hemolytic Anemia

Interventions: Drug: povetacicept

First Posted Date: 2023-03-07

Last Posted Date: 2024-12-27

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 126

Registration Number: NCT05757570

Locations: 🇬🇧
Investigational Site (442), Leeds, United Kingdom
🇬🇧
Investigational Site (439), London, United Kingdom
🇬🇧
Investigational Site (440), London, United Kingdom

and more 41 locations

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases

Phase 1

Recruiting

Conditions: Lupus Nephritis
Immunoglobulin A Nephropathy
Membranous Nephropathy
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions: Drug: povetacicept

First Posted Date: 2023-02-17

Last Posted Date: 2024-07-19

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 56

Registration Number: NCT05732402

Locations: 🇺🇸
Investigational Site (523), Phoenix, Arizona, United States
🇰🇷
Investigational Site (507), Cheonan, Chungcheongnam-do, Korea, Republic of
🇺🇸
Investigational Site (524), Tucson, Arizona, United States

and more 25 locations

A Study of ALPN-303 in Adult Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Placebo
Drug: ALPN-303

First Posted Date: 2021-09-05

Last Posted Date: 2023-05-09

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 72

Registration Number: NCT05034484

Locations: 🇦🇺
Investigative Site, Melbourne, Victoria, Australia

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Solid Tumor
Lymphoma

Interventions: Drug: ALPN-202
Drug: pembrolizumab KEYTRUDA®

First Posted Date: 2021-06-09

Last Posted Date: 2024-03-01

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 29

Registration Number: NCT04920383

Locations: 🇺🇸
Investigational Site (212), Boston, Massachusetts, United States
🇺🇸
Investigational Site (213), Atlanta, Georgia, United States
🇺🇸
Investigational Site (301), Grand Rapids, Michigan, United States

and more 2 locations

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: ALPN-101
Drug: Placebo

First Posted Date: 2021-04-08

Last Posted Date: 2024-04-29

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 130

Registration Number: NCT04835441

Locations: 🇺🇸
Investigational Site (173), Idaho Falls, Idaho, United States
🇺🇸
Investigational Site (118), Colleyville, Texas, United States
🇵🇷
Investigational Site (191), Caguas, Puerto Rico

and more 43 locations

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD

Phase 1

Terminated

Conditions: Graft Vs Host Disease

Interventions: Drug: ALPN-101

First Posted Date: 2020-01-14

Last Posted Date: 2023-08-28

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 1

Registration Number: NCT04227938

Locations: 🇺🇸
University of Kansas Hospital, Kansas City, Kansas, United States
🇺🇸
St. David's South Austin medical Center, Austin, Texas, United States
🇺🇸
University of Miami, Miami, Florida, United States

and more 1 locations

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

Phase 1

Terminated

Conditions: Advanced Solid Tumor
Lymphoma

Interventions: Drug: ALPN-202

First Posted Date: 2019-12-05

Last Posted Date: 2023-06-05

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 62

Registration Number: NCT04186637

Locations: 🇺🇸
Investigational Site (007), Lafayette, Indiana, United States
🇦🇺
Investigational Site (101), Melbourne, Victoria, Australia
🇺🇸
Investigational Site (009), Portland, Oregon, United States

and more 7 locations

Cell Surface Marker Expression in Autoimmune Diseases

Completed

Conditions: Systemic Sclerosis
Crohn's Disease
Ulcerative Colitis
Sjogren's Syndrome
Systemic Lupus Erythematosus
Multiple Sclerosis
Inflammatory Myositis

First Posted Date: 2018-11-28

Last Posted Date: 2020-08-27

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 14

Registration Number: NCT03757065

Locations: 🇨🇦
Mary Pack Arthritis Center, Vancouver, Canada
🇨🇦
GI Research Institute, Vancouver, British Columbia, Canada

Adult Healthy Volunteers Study to Evaluate ALPN-101 Safety

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: ALPN-101
Drug: Placebo

First Posted Date: 2018-11-21

Last Posted Date: 2019-12-05

Lead Sponsor: Alpine Immune Sciences, Inc.

Target Recruit Count: 96

Registration Number: NCT03748836

Locations: 🇦🇺
Nucleus Network- Centre for Clinical Studies, Melbourne, Victoria, Australia

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy